XML 24 R15.htm IDEA: XBRL DOCUMENT
v3.23.2

RESTRUCTURING CHARGES | 6 Months Ended
--- | ---
Jun. 30, 2023
Restructuring and Related Activities [Abstract] |
RESTRUCTURING CHARGES | RESTRUCTURING CHARGESOn April 26, 2023, the Company executed a restructuring of operations and a corresponding reduction in workforce (the “Restructuring”), designed to reduce costs and increase focus on the following strategic priorities: (i) preclinical neurology disease epigenetic regulation portfolio, including its Nav 1.7 and prion disease programs, (ii) potential Phase 3 trial of isaralgagene civaparvovec, the Company’s gene therapy to treat Fabry disease, and (iii) continuation of the Phase 1/2 STEADFAST study, which evaluates TX200, its wholly owned autologous CAR-Treg cell therapy to treat patients receiving an HLA-A2 mismatched kidney from a living donor. The Restructuring resulted in the elimination of approximately 110 roles, including 55 full-time employees and 55 contracted employees and eliminated open positions, in the United States, or approximately 23% of the total United States workforce as of April 26, 2023, and included one-time severance payments and other employee-related costs, including additional vesting of service-based stock compensation awards. The Company incurred approximately $5.3 million of expenses related to the Restructuring in the three and six months ended June 30, 2023, of which $4.1 million is included in research and development expense and $1.2 million is included in general and administrative expense in the accompanying Condensed Consolidated Statements of Operations. The Company expects a majority of the cash payments related to the Restructuring to be substantially completed in the third quarter of 2023, and the Restructuring to be completed by the end of the third quarter of 2024. The following table is a summary of accrued Restructuring costs included within other accrued liabilities on the Company’s Condensed Consolidated Balance Sheet as of June 30, 2023 (in thousands):
| Six Months Ended June 30, 2023
Balance at December 31, 2022 | $ | — |
Restructuring charges | 5,337 |
Cash payments | (1,180) |
Non-cash adjustments | (305) |
Balance at June 30, 2023 | $ | 3,852 |

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//420/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration